ORGO - Organogenesis gets FDA clearance for PuraPly MZ for wound healing

• Organogenesis ( NASDAQ: ORGO ) said the U.S. Food and Drug Administration (FDA) granted 510k clearance to would healing product PuraPly MZ.
• The company added that PuraPly MZ uses the properties of its PuraPly technology engineered into a micronized (powdered) form to provide surgeons with an option for complex surgical wounds.
• "Securing FDA Clearance for PuraPly MZ is a significant milestone for the company as we continue to expand into the surgical and sports medicine market," said Organogenesis President and CEO Gary Gillheeney Sr.
• The company noted that PuraPly MZ consists of native structured collagen which allows for maximum coverage and maintenance of optimal contact with the contours of the wound surface to support healing.
• ORGO +3.60% $4.89 premarket Aug. 15

For further details see: